Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.

Abstract

OBJECTIVE:

Pyrotinib is a novel EGFR/HER2 dual tyrosine kinase inhibitor developed in China, while its role in neoadjuvant therapy of HER2-positive (HER2+) breast cancer lacks evidence. The current study aimed to explore the efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide (TAC) for HER2+ breast cancer.

METHODS:

A total of 27 HER2+ breast cancer patients received neoadjuvant pyrotinib plus TAC for 6 cycles, then surgery was performed. The clinical and pathological responses, and adverse events were evaluated.

RESULTS:

Complete response rate, objective response rate, and disease control rate were 0.0%, 44.4% and 100.0% after 2 treatment cycles; 0.0%, 37.0%, and 100.0% after 4 treatment cycles; 37.0%, 37.0%, and 96.3% after 6 treatment cycles; as well as 37.0%, 44.4%, and 100.0% based on the best clinical response. Regarding pathological response, there were 1 (2.7%), 3 (11.1%), 8 (29.6%), 5 (18.5%), and 10 (37.0%) patients realizing Miller-Payne grade (G) 1, G2, G3, G4, and G5, respectively; besides, 10 (37.0%) patients achieved total pathological complete response (pCR), 10 (37.0%) patients realized pCR in breast, and 23 (85.2%) patients achieved pCR in lymph node. Additionally, adverse events included diarrhea (81.5%), dental ulcer (7.4%), and hand-foot syndrome (3.7%); meanwhile, grade 3-4 adverse event consisted of only diarrhea (11.1%).

CONCLUSION:

Neoadjuvant pyrotinib plus TAC treatment is efficient and safe in HER2+ breast cancer patients, while further validation is needed.

• Authors: Chunyu Tian, Minghui Wang, Hancheng Liu, Jianping Liu, Mengze Xu, Lihui Ma
• Journal: Irish journal of medical science (Ir J Med Sci) Vol. 192 Issue 3 Pg. 1041-1049 (Jun 2023) ISSN: 1863-4362 [Electronic] Ireland
• PMID: 35829909 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

Chemical References

• Docetaxel
• pyrotinib
• liposomal doxorubicin
• Cyclophosphamide
• Receptor, ErbB-2

Topics

• Humans
• Female
• Breast Neoplasms (drug therapy, surgery)
• Docetaxel (therapeutic use)
• Neoadjuvant Therapy
• Cyclophosphamide (adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Receptor, ErbB-2